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INTRODUCTION

36
Tregs are potent suppressors of immune responses 1, 2 , and defects in Treg development and/or function 37 can underlie devastating autoimmune disorders [3] [4] [5] . The majority of Tregs under physiological conditions 38 are naïve, with little overt suppressor activity. Upon antigen and cytokine stimulation, naïve Tregs 39 become activated and differentiated into effector cells expressing various cell surface and soluble 40 molecules that mediate suppressor function 1, [6] [7] [8] [9] . It is therefore of great interest to characterize the 41 mechanisms controlling Treg activation and effector function. TAM (25.2 vs. 28.8g). Nevertheless, by Day 251, this mouse seemed to have become otherwise 151 perfectly healthy, devoid of any overt sign of illness such as skin lesions and lethargy (not shown).
153
Collectively, these data reveal powerful effects of Brg1 reexpression on the sick mice, with as little as 8%
154
of Brg1-reexpressed Tregs sufficient for the rescue in some cases.
156
Brg1 reexpression, presumably in conjunction with excessive cytokine stimulation, produced 157 hyperactivated, highly suppressive "SuperTregs"
158
To characterize Brg1-reexpressed Tregs, we treated 3-wks-old rKO1 mice with the low dose of TAM and 159 compared gene expression patterns in Brg1-deleted (GFP + ) vs. Brg1-reexpressed (GFP -) Treg subsets 160 isolated 7 days after TAM, when the two populations were cleanly distinguishable ( Fig. 1F ). This analysis 161 would reveal the role of Brg1 in partially activated Tregs exposed to inflammation. As a control, we 162 addressed the role of Brg1 in Tregs under the physiological condition. To this end, we compared Brg1-163 deleted (YFP + ) and Brg1-sufficient (YFP -) Tregs from the healthy, mosaic females (Brg1 F/ΔR ; FoxP3 YFP-164 Cre/+ ; R26 CAG-FlpoER/ CAG-FlpoER , where YFP-Cre was expressed in only half of the Tregs due to random X-165 inactivation; these mice also carried R26 CAG-FlpoER/ CAG-FlpoER just as the rKO1 mice in order to control for 166 any potential nonspecific confounding effects of FlpoER expression when comparing differentially 167 expressed genes between the two strains). As additional controls, we used Tregs isolated from WT mice 168 and from rKO1 mice not treated with TAM, the former being Brg1-sufficient while the latter Brg1-deficient, 169 therefore comparable to Brg1-sufficient Tregs from the mosaic females and the Brg1-deficient Tregs from 170 TAM-treated rKO1 mice, respectively. All the mice were 3-4 weeks old when sacrificed.
172
Brg1-deletion in the mosaic females and Brg1-reexpression in rKO1 mice on Day 7 after TAM treatment 173 affected 618 and 1352 genes, respectively, with only 241 genes shared, suggesting divergent roles of 174 Brg1 under the physiological vs. inflammatory conditions ( Fig. 3A ; see Supplemental Data for complete 175 list of these genes; raw data already deposited). Brg1-target genes are of diverse functions, a 176 conspicuous group being related to Treg function (Fig. 3B ). These genes can be divided into two 9 categories: the "naïve genes" that are predominantly expressed in naïve Tregs (Bach2 and Ccr7) 8,19 , 178 and "activation/effector function genes" preferentially expressed in activated/effector Tregs, including 179 Icos 8 , Tigit 20 ,Cxcr3 21 , Klrg1 22 , Prdm1 23 and Gzmb 24 . In the Brg1 KO Tregs within the mosaic females, 180 the "naïve genes" were upregulated, while most of the "activation/effector function genes" repressed, 181 relative to the Brg1-sufficient Tregs in both the mosaic females and the WT mice (lane 3 vs. 1-2), 182 confirming that the direct effect of Brg1 deletion was to inhibit Treg activation 17 . Interestingly, in the rKO1 183 mice with severe inflammation, the Brg1 KO Tregs were partially/weakly activated, with the "naïve genes" 184 repressed and some of the "activation/effector function genes" (i.e.,Cxcr3, Gzma, Gzmb,Gzmf) 185 upregulated relative to the Brg1-sufficient controls (lane 4 vs. 1-2). These data reinforce the notion that suppressive. The data also demonstrate that although the Brg1 target genes were in general highly 195 divergent in the mosaic (healthy) vs. rKO1(inflamed) mice ( Fig. 3A) , the Brg1-controlled transcription 196 program underlying Treg activation was conserved between the two distinct conditions, but with a twist: 197 in the rKO1 mice, BRG1 was able to upregulate the activation markers to much higher levels than in 198 mosaic mice (lane 6 vs. 2), which seemed to reflect (in part) a synthetic effect of cytokine stimulation in Consistent with the increased proliferation, Brg1-reexpressed Tregs became somewhat more abundant 205 after TAM treatment (not shown). Curiously, the pro-survival Birc5 was also upregulated in SuperTregs, 206 perhaps reflecting a negative feedback effect ( Fig. 3C ).
208
We next used FACS to validate the RNA-seq results. SuperTregs were indeed more proliferative and 209 more apoptotic (Fig. 3D ). To assay their suppressive function, dye-labeled conventional CD4 cells 210 (Tconv) were stimulated with antigen presentation cells and anti-CD3 for 5 days in the presence or 211 absence of Tregs before the FACS analysis. In the absence of Tregs, 72% of the Tconv survived and 
217
Finally, we have begun to define the mechanism underlying gene hyperactivation in SuperTregs, namely, 218 how BRG1 in the inflamed rKO1 mice could upregulate the activation markers to much higher levels than 219 BRG1 in the healthy mosaic or WT mice (lane 6 vs. 1-2). To address this issue, we used Cxcr3 as a 220 model. Cxcr3 marks the Treg subset specialized in suppressing the Th1 response 21 . It is a direct target of 221 BRG1 17 and hyperactivated in SuperTregs ( Fig. 3B ). Importantly, Cxcr3 is induced in response to IFNγ 222 stimulation, perhaps in conjunction with TCR signaling 21 . Given that Cxcr3 is subject to joint regulation by 223 BRG1 and IFNγ /TCR, our hypothesis is that in rKO1 mice with severe inflammation, Tregs experience 224 enhanced IFNγ /TCR stimulation, which can conceivably complement BRG1 to induce strong Cxcr3 225 expression. Indeed, in ~3 weeks-old rKO1 mice with severe inflammation, STAT1 phosphorylation in Our data collectively suggest that Brg1 reexpression acted (partly) in conjunction with inflammatory 230 cytokines to convert Brg1-deleted Tregs into hyperactivated Tregs endowed with potent suppressive 231 activity.
233
The fate of SuperTreg in vivo 234 We have followed SuperTregs in the five TAM-treated rKO2 mice ( increased (to 20.6% from 9.5% on Day 56, Fig. 4A , row 1). To determine whether this increase was due 257 to the accumulation of the GFP -Treg subset and/or depletion of the GFP + Treg subset, we examined the 258 abundance of the two Treg subsets relative to that of conventional CD4 cells, finding that the increased 259 frequency of the GFPsubset was due to its accumulation, as the abundance of the GFP + subset 
268
The reciprocal changes in the abundance of the GFPvs GFP + Treg subsets were also observed ( Fig. 4B , 269 top right, thin lines). Finally, we also followed the fate of the 3 rKO1 mice treated with the low-dose TAM 270 regimen, with similar findings (Fig. S2B ).
272
We conclude that SuperTregs tended to lose the hyper-activated phenotype as the inflammation 273 subsided, suggesting that the inflammatory environment was essential for maintaining Treg 274 hyperactivation. Our data also support the notion that the enhancement of Treg suppressive function in 275 response to inflammation is "memory-less", a feature important for avoiding generalized 276 immunosuppression that could otherwise result from repeated activation 9 .
1 3
DISCUSSION
278
Using conventional gene KO technologies, many genes have been identified that affect Treg function 279 and immune tolerance. The current work is the first to address the effects of reversing the KO, which 280 provides insights hard to obtain using conventional KO models, as discussed below.
282
Consequences of Brg1 KO and reexpression in Tregs
283
These are summarized in Fig. 5 , which is based on the current and the previous work 17 . Specifically, in
284
WT mice, when antigens activate conventional T cells, Tregs also get activated to restrict the immune 285 response. In rKO mice, Brg1 KO impairs Treg activation, leading to the onset of inflammation. As the 286 inflammation intensifies, Tregs get partially activated (partly) by inflammatory stimuli such as IFNγ, but 287 this is insufficient to stop the ongoing inflammation (dotted line). Importantly, at this point, when Brg1 is 288 re-expressed upon TAM administration, it acts in conjunction with the inflammatory stimuli to convert the 289 functionally compromised Tregs into hyperactivated "SuperTregs", which overwhelm the inflammation.
290
As the inflammation is resolved, SuperTregs reverse activation-induced changes (not depicted).
292
A few issues are noteworthy regarding this model.
294
First, we wish to reiterate that compared with the activated Tregs in the WT mice, the activated Tregs in 295 the SuperTreg population were not only more abundant, but also expressed higher levels of some 296 activation markers (like ICOS). Thus, SuperTregs showed both quantitative and qualitative differences 297 from the activated Tregs in the WT mice.
299
Second, TAM treatment should also lead to Brg1 reexpression in the Treg precursors in the thymus and 300 bone marrow, and the nascent, Brg1-sufficient Tregs might also contribute to the resolution of 301 inflammation. However, this contribution might be minimal, given the low rate of T cell production in adult 302 mice, especially in the sick mice where the thymi were profoundly atrophic as a result of inflammatory 303 stress (not shown).
4
Third, Brg1-reexpressed Tregs had markedly accumulated by 5 months after the low-dose TAM 305 treatment, which should ensure permanent benefit of the treatment.
307
Finally, excessive STAT1 signaling (caused e.g. by Treg-specific SOCS1 ablation) is known to cause 308 CXCR3 overexpression, which paradoxically impairs the ability of Tregs to control Th1 response, in 309 apparent conflict with our observation 25 . We note that the CXCR3 is much more overexpressed in the 
328
Medical relevance of the current study
329
Our study has therapeutic implications for heritable autoimmune disorders resulting from Treg defects, 330 the best defined being the immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) 1 5 resulting from FOXP3 mutations 3-5 . The IPEX phenotypes tend to vary with the nature of the mutations.
332
For example, missense mutations and promoter mutations can be associated with normal Treg numbers 333 (but compromised Treg suppressive function) and a milder phenotype. In addition to FoxP3, mutations at 334 a number of other genes important for Treg function (including CD25 , STAT5b, ITCH and STAT1) are 335 known to cause IPEX-like disorders 5 . Treatment options for the IPEX disorder are limited mainly to 336 immunosuppressive drugs and allogeneic hematopoietic stem cell transplantation (HSCT).
337
Immunosuppressive therapy is beneficial only temporarily, as it fails to prevent disease progression in 338 most patients, with the overall survival rate being only 65% at 24 years of age 4 . HSCT does not improve 339 the survival rate, and furthermore, some patients cannot undergo HSCT due to limited donor availability 340 or because their clinical manifestations are not severe enough to justify HSCT 4,29 . Effective therapies for 341 IPEX-like disorders similarly remain elusive.
343
We envision an alternative strategy for treating IPEX(-related) disorders. In contrast to HSCT, our 344 strategy exploits preexisting defective Tregs. Specifically, we propose to correct the genetic defects in 
353
The efficiency of gene-editing determines the therapeutic efficacy. Gene editing tools vary in efficiency.
354
Fortunately, the highly effective "base editors" that can change A>G or C>T have been developed 30,31 , 355 which is applicable to, for example, the many IPEX patients carrying a single G>A substitution at FoxP3 4 .
356
The base editor together with relevant gRNA expression cassette might be delivered systemically into 357 such patients using a lentiviral vector, such as the CD4-targeted lentiviral vector that transduces up to 7% 
370
except that the homology arms in the Baf57 Δ R targeting construct were replaced with the sequences 371 from the Brg1 locus (Fig. 1A) . The rKO mice were then created by introducing Brg F 36 , R26 CAG-FlpoER 37 and 372 FoxP3 YFP-Cre 38 into the Brg1 Δ R/+ mice. Of note, this breeding scheme also generated conventional, 373 irreversible KO littermates, whose genotypes were identical to rKO except that both alleles of Brg1 were 374 floxed. Interestingly, the phenotype of these littermates were generally weaker than rKO mice (but similar 375 to the conventional Brg1 KO mice previously described 17 , presumably because the conventional KO mice (E/M) and naïve CD4 cells in peripheral blood. TAM (full dose) was given to 3-wks-old rKO mice (Day 0).
547
Blue and red asterisks denote statistical significance (p<0.05) when Naïve and E/M CD4 frequencies, 548 respectively, were compared between rKO1 and WT mice. (F) Low-dose TAM regimen fully rescued 549 rKO2 mice (p<0.05). For comparison, the survival curve for the rKO1 mice ( Fig. 2A) (A) Peripheral blood cells from the rKO2 mouse with 8% GFP -Tregs (Fig. 2H , thick blue line) were 571 stained with a mixture of CD4, KLRG1, ICOS, TIGIT and CXCR3 antibodies for the analysis of ICOS,
572
TIGIT and CXCR3 expression in KLRG1 + and KLRG1subsets (row 2-4) within the GFP -(column 3,5,7)
573 and GFP + (column 1,2,4,6,8) Treg populations. (B) Summary of the FACS results for the mouse 574 analyzed in Fig. 4A (mouse #1) , together with the four other mice in Fig. 2H (#2-5) . For clarity, only the 575 GFP-subset is displayed for mouse #1 in all the plots except the top right plot, and only Mean +/-SM is 576 displayed for Mice #2-5. As the rKO mice (bearing 5-6 alleles) were quite rare, the 5 mice were born and 577 hence analyzed at different times, except for the last two time points when the mice from different litters re-expressed Tregs (28%) is highlighted with thick blue line. As the rKO mice (bearing 5-6 alleles) were 588 quite rare, the 3 mice were born and hence analyzed at different times, except for the last two time points 589 when the mice from different litters were analyzed together. The control mice were the same as those 590 used for the rKO2 mice ( Fig. 2H; Fig. 4 ). (B) SuperTreg fate, analyzed as for rKO2 in Fig. 4 . 
Fig. 2. Effects of Brg1 reexpression on rKO mice (A)
Survival of rKO1 mice. rKO1 mice were either Brg1 F/ΔR ; FoxP3 YFP-Cre ; R26 CAG-FlpoER/CAG-FlpoER males or Brg1 F/ΔR ; FoxP3 YFP-Cre/YFP-Cre ; R26 CAG-FlpoER/CAG-FlpoER females. Littermate controls were of the same genotypes except they carried either Brg1 F/+ or Brg1 ΔR/+ and thus heterozygous for Brg1. For convenience, these controls were labeled "WT" throughout the paper. The rKO1 mice treated with full dose of TAM lived significantly longer than rKO1 (p<0.05). (B) Representative image of rKO1 mice before and after TAM treatment (full dose). (C) Body weight gain of rKO1 mice following TAM treatment(full dose).* and **, p<0.05 and 0.01, respectively. (D-E) Abundance of effector/memory-like (E/M) and naïve CD4 cells in peripheral blood. TAM (full dose) was given to 3-wks-old rKO mice (Day 0). Blue and red asterisks denote statistical significance (p<0.05) when Naïve and E/M CD4 frequencies, respectively, were compared between rKO1 and WT mice. (F) Low-dose TAM regimen fully rescued rKO2 mice (p<0.05). For comparison, the survival curve for the rKO1 mice ( Fig. 2A) is also displayed (red line). (G) rKO2 were nearly as runted as rKO1. (H) Body weight (left) and E/M CD4 cells (right) of the 5 TAM-treated rKO2 mice in Fig. 2F . The mean values (+/-SE) of WT littermates are also plotted (dotted lines). As the rKO mice (bearing 5-6 alleles) were quite rare, the 5 mice were born and hence analyzed at different times, except for the last two time points when the mice from different litters were analyzed together (the mouse with 8% reversal analyzed on Day 151 and 251). CD4 cells, labeled with CellTracer, were stimulated with APC and anti-CD3 in the presence or absence of Tregs for 5 days before analyzing 7AAD and CellTracer fluorescence (E). The CellTracer MFI of the viable (7AAD -) cells in the presence of Tregs were plotted relative to that in the absence of Tregs, as are the relative viable cell frequencies plotted (F). In E, the Treg: Tconv ratio was 1:4. A replica of this experiment is shown in Fig. S3 . (G) IFNg -STAT1 and TCR-AKT signaling in splenic Tregs. To quantify STAT1 (Y701) phosphorylation, the STAT1 (Y701) MFI for rKO1 Tregs was normalized to the WT controls, the latter set as 1 (middle).
WT rKO1 SuperTreg
WT rKO1
Brg1 target genes in Tregs Fig. 2H . The mouse with least Brg1 re-expressed Tregs (28%) is highlighted with thick blue line. As the rKO mice (bearing 5-6 alleles) were quite rare, the 3 mice were born and hence analyzed at different times, except for the last two time points when the mice from different litters were analyzed together. The control mice were the same as those used for the rKO2 mice ( Fig. 2H; Fig. 4 ). (B) SuperTreg fate, analyzed as for rKO2 in Fig. 4 . 
